{"id":"high-titer-anti-influenza-plasma","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Volume overload"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This convalescent plasma product contains elevated concentrations of anti-influenza antibodies harvested from donors who have recovered from influenza infection. These antibodies directly neutralize circulating influenza virus particles and enhance immune clearance, providing immediate passive immunity to patients with acute or severe influenza. The approach leverages the donor's adaptive immune response to provide rapid therapeutic benefit without requiring the recipient's own immune system to generate antibodies.","oneSentence":"High-titer anti-influenza plasma provides passive immunotherapy by transferring high levels of neutralizing antibodies from recovered influenza patients to treat active influenza infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:56.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute influenza infection in hospitalized patients"},{"name":"Severe influenza with respiratory complications"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00984451","phase":"","title":"A Pilot Study for Collection of Anti-Influenza A Immune Plasma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-09","conditions":"Influenza A Virus Infection, Swine Flu","enrollment":102},{"nctId":"NCT02572817","phase":"PHASE3","title":"Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11","conditions":"Influenza A Virus Infection","enrollment":138},{"nctId":"NCT01136057","phase":"","title":"Blood and Plasma Collection For Use in Future Clinical Trials","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-04","conditions":"Influenza A Virus Infection","enrollment":21},{"nctId":"NCT00383071","phase":"PHASE2","title":"Development of Immune Globulin Treatment for Avian Flu","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-08","conditions":"Infectious Diseases, Influenza, Avian Flu","enrollment":126},{"nctId":"NCT01052480","phase":"PHASE2","title":"Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-12","conditions":"Influenza A, Influenza B","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"High-titer anti-influenza plasma","genericName":"High-titer anti-influenza plasma","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"High-titer anti-influenza plasma provides passive immunotherapy by transferring high levels of neutralizing antibodies from recovered influenza patients to treat active influenza infection. Used for Acute influenza infection in hospitalized patients, Severe influenza with respiratory complications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}